Literature DB >> 26546359

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.

F Efficace1, G Rosti2, M Breccia3, F Cottone4, J M Giesinger4, F Stagno5, A Iurlo6, A Russo Rossi7, L Luciano8, B Martino9, S Galimberti10, D Turri11, M Bergamaschi12, M Tiribelli13, C Fava14, E Angelucci15, F Mandelli4, M Baccarani2.   

Abstract

The primary objective of this study was to investigate whether the presence of comorbidities was associated with a lower health-related quality of life (HRQOL) in elderly patients with chronic myeloid leukemia (CML). A sample of 174 CML patients aged 60 years or above was analyzed. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). A number of pre-selected sociodemographic and disease-related factors were considered as potential confounding factors for the association between comorbidity and HRQOL. Mean age of the 174 patients analyzed was 70 years (range 60-87 years) and 55 % were male. Overall, 111 patients (64 %) reported at least one comorbidity. Analysis stratified by age group category showed a greater proportion of patients with comorbidities in the older sub-group population (≥70 years) compared to younger patients (60 to 69 years). Differences in HRQOL outcomes between patients with no comorbidity at all and those with two or more comorbid conditions were at least twice the magnitude of a clinically meaningful difference in all the physical and mental health scales of the SF-36. In multivariate analysis, after adjusting for key confounding factors, the following scales were significantly lower in those with comorbidity: general health (p < 0.001), bodily pain (p < 0.001), physical functioning (p = 0.002), and vitality (p = 0.002). Assessing comorbidity in elderly patients with CML is important to facilitate identification of those most in need of HRQOL improvements.

Entities:  

Keywords:  Chronic myeloid leukemia; Comorbidity; Quality of life

Mesh:

Year:  2015        PMID: 26546359     DOI: 10.1007/s00277-015-2541-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.

Authors:  Qian Jiang; Hai-Bo Wang; Lu Yu; Robert Peter Gale
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-01       Impact factor: 4.553

2.  EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.

Authors:  Micha J Pilz; Eva-Maria Gamper; Fabio Efficace; Juan I Arraras; Sandra Nolte; Gregor Liegl; Matthias Rose; Johannes M Giesinger
Journal:  BMC Public Health       Date:  2022-05-24       Impact factor: 4.135

Review 3.  The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Authors:  Guray Saydam; Ridvan Ali; Ahmet Muzaffer Demir; Ahmet Emre Eskazan; Birol Guvenc; Ibrahim Celalettin Haznedaroglu; Mehmet Ali Ozcan; Ozan Salim; Mehmet Sonmez; Ayse Tulin Tuglular; Mehmet Turgut; Ali Unal; Birkan Aver; Sirac Bozkurt; Begum Ozdengulsun; Osman Ilhan
Journal:  Int J Hematol Oncol       Date:  2022-05-24

4.  Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.

Authors:  Qian Jiang; Haibo Wang; Lu Yu; Robert Peter Gale
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-11       Impact factor: 4.553

5.  Effects of Chronic Comorbidities on the Health-Related Quality of Life among Older Patients after Falls in Vietnamese Hospitals.

Authors:  Hai Minh Vu; Long Hoang Nguyen; Tung Hoang Tran; Kiet Tuan Huy Pham; Hai Thanh Phan; Hieu Ngoc Nguyen; Bach Xuan Tran; Carl A Latkin; Cyrus S H Ho; Roger C M Ho
Journal:  Int J Environ Res Public Health       Date:  2019-09-27       Impact factor: 3.390

6.  Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.

Authors:  Guray Saydam; Ali Unal; Ibrahim Celalettin Haznedaroglu; Abdullah Hacihanifioglu; Ozgur Mehtap; Erdal Kurtoglu; Mesut Gocer; Mehmet Turgut; Engin Kelkitli; Memis Hilmi Atay; Nil Guler; Basak Unver Koluman; Mehmet Sonmez; Nergiz Erkut; Emin Kaya; Irfan Kuku; Mehmet Ali Erkurt; Gulsum Ozet; Funda Ceran; Fahri Sahin; Nur Soyer; Meliha Nalcaci; Mehmet Yilmaz; Sirac Bozkurt; Birkan Aver; Begum Ozdengulsun; Egemen Ozbilgili; Osman Ilhan
Journal:  Int J Hematol Oncol       Date:  2022-06-30

7.  Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Authors:  Alessandra Iurlo; Alessandro Nobili; Roberto Latagliata; Cristina Bucelli; Fausto Castagnetti; Massimo Breccia; Elisabetta Abruzzese; Daniele Cattaneo; Carmen Fava; Dario Ferrero; Antonella Gozzini; Massimiliano Bonifacio; Mario Tiribelli; Patrizia Pregno; Fabio Stagno; Paolo Vigneri; Mario Annunziata; Francesco Cavazzini; Gianni Binotto; Giovanna Mansueto; Sabina Russo; Franca Falzetti; Enrico Montefusco; Gabriele Gugliotta; Sergio Storti; Ada M D'Addosio; Luigi Scaffidi; Laura Cortesi; Michele Cedrone; Antonella Russo Rossi; Paolo Avanzini; Endri Mauro; Antonio Spadea; Francesca Celesti; Gianfranco Giglio; Alessandro Isidori; Monica Crugnola; Elisabetta Calistri; Federica Sorà; Giovanna Rege-Cambrin; Simona Sica; Luigiana Luciano; Sara Galimberti; Ester M Orlandi; Monica Bocchia; Mauro Tettamanti; Giuliana Alimena; Giuseppe Saglio; Gianantonio Rosti; Pier Mannuccio Mannucci; Agostino Cortelezzi
Journal:  Oncotarget       Date:  2016-11-29

8.  Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.

Authors:  Tim H Brümmendorf; Carlo Gambacorti-Passerini; Andrew G Bushmakin; Joseph C Cappelleri; Andrea Viqueira; Arlene Reisman; Susanne Isfort; Carla Mamolo
Journal:  Ann Hematol       Date:  2020-04-19       Impact factor: 3.673

9.  Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.

Authors:  Lu Yu; Haibo Wang; Darko Milijkovic; Xiaojun Huang; Qian Jiang
Journal:  BMC Cancer       Date:  2018-08-03       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.